Sfoglia per AUTORE
DI RAIMONDO F
Collezione AO Cuneo

  

Items : 17

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study. in Leukemia / Leukemia. 2023 Apr;37(4):914-918. doi: 10.1038/s41375-023-01845-9. Epub 2023 Feb 18.

2023
AO Cuneo

Gattei V; Del Poeta G; Foà R; Di Raimondo F; Tafuri A; Zaja F; Fronza G; Morabito F; Gentile M; Cuneo A; Del Principe MI; Postorino M; Laureana R; Olivieri J; Chiarenza A; Reda G; Laurenti L; Marasca R; Bulian P; Degan M; Polesel J; Tissino E; Pozzo F; Zucchetto A; Papotti R; Vit F; Bittolo T; Rossi FM; Bomben R; et alii...

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. in American journal of hematology / Am J Hematol. 2021 May 1;96(5):E168-E171. doi: 10.1002/ajh.26127. Epub 2021 Feb 24.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Gentile M; Gattei V; Foà R; Ferrarini M; Polliack A; Gaidano G; Trentin L; Cuneo A; Fronza G; Cutrona G; Rossi D; Di Raimondo F; Neri A; Bomben R; Biagi A; Del Giudice I; Angeletti I; Galimberti S; Rago A; Caracciolo D; Cassin R; D'Arrigo G; Mendicino F; Botta C; Martino EA; Vigna E; Zucchetto A; Rossi FM; Scortechini I; et alii...

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. in Haematologica / Haematologica. 2021 Jun 1;106(6):1559-1568. doi: 10.3324/haematol.2020.247973.

2021
AOU Città della Salute di Torino
AO Cuneo

Vitale A; Cattaneo C; Mattei D; Fracchiolla N; Cerrano M; Cairoli R; Candoni A; Papayannidis C; De Fabritiis P; Di Raimondo F; Capria S; Apicella V; Spinelli O; Santoro A; Pierini V; Puzzolo MC; Lauretti A; Canichella M; La Starza R; Albertini Petroni G; Elia L; Ansuinelli M; Taherinasab A; Cavalli M; Cafforio L; Piciocchi A; Della Starza I; Messina M; Chiaretti S; et alii...

Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. in Leukemia / Leukemia. 2021 Jan;35(1):235-238. doi: 10.1038/s41375-020-0833-x. Epub 2020 Apr 14.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Sportoletti P; Laurenti L; Gattei V; Gaidano G; Polliack A; Foà R; Rossi D; Cuneo A; Di Raimondo F; Rigolin GM; Bomben R; Biagi A; Del Giudice I; Angeletti I; Rago A; Arrigo G; Vigna E; Botta C; Tripepi G; Fraticelli V; Zucchetto A; Scortechini I; Loseto G; Consoli U; Rossi FM; Pietrasanta D; Murru R; Chiarenza A; Condoluci A; et alii...

TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. in American journal of hematology / Am J Hematol. 2021 Aug 1;96(8):E306-E310. doi: 10.1002/ajh.26235. Epub 2021 May 25.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Gentile M; Gattei V; Ferrarini M; Foà R; Polliack A; Trentin L; Cuneo A; Gaidano G; Di Raimondo F; Rossi D; Olivieri J; Jaksic O; Bomben R; Neri A; Fronza G; Rago A; Angeletti I; Cutrona G; Del Giudice I; Biagi A; Galimberti S; D'Arrigo G; Al-Janazreh H; Martino EA; Vigna E; Tripepi G; Zucchetto A; Rossi FM; Recchia AG; et alii...

Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials. in American journal of hematology / Am J Hematol. 2021 Aug 1;96(8):E269-E272. doi: 10.1002/ajh.26201. Epub 2021 May 3.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

D Arrigo G; Murru R; Gentile M; Gattei V; Polliack A; Trentin L; Gaidano G; Di Raimondo F; Cuneo A; Cutrona G; Rossi D; Menichini P; Olivieri J; Fronza G; Monti P; Del Giudice I; Bomben R; Neri A; Angeletti I; Biagi A; Rago A; Martino EA; Cassin R; Galimberti S; Foà R; Ferrarini M; Scortechini I; Rossi FM; Zucchetto A; et alii...

Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. in European journal of haematology / Eur J Haematol. 2021 Apr;106(4):493-499. doi: 10.1111/ejh.13573. Epub 2021 Jan 28.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Gentile M; Gattei V; Ferrarini M; Foà R; Trentin L; Polliack A; Gaidano G; Cuneo A; Di Raimondo F; Rossi D; Jaksic O; Monti P; Cutrona G; Bomben R; Neri A; Fronza G; Menichini P; Biagi A; Del Giudice I; Angeletti I; Rago A; Galimberti S; Cassin R; D'Arrigo G; Mendicino F; Martino EA; Vigna E; Al-Janazreh H; Zucchetto A; et alii...

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. in Blood cancer journal / Blood Cancer J. 2020 Sep 16;10(9):92. doi: 10.1038/s41408-020-00358-3.

2020
AOU Città della Salute di Torino
AO Cuneo
AOU Alessandria
AOU Novara

Gattei V; Morabito F; Ferrarini M; Gaidano G; Cuneo A; Foà R; Trentin L; Fronza G; Cutrona G; Di Raimondo F; Angeletti I; Bomben R; Neri A; D'Arrigo G; Tripepi G; Vitale C; Al-Janazreh H; Rossi FM; Zucchetto A; Scortechini I; Consoli U; Loseto G; Pietrasanta D; Bossio S; Moia R; Recchia AG; Lucia E; Mendicino F; Vigna E; et alii...

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. in Cancer medicine / Cancer Med. 2020 Nov;9(22):8468-8479. doi: 10.1002/cam4.3470. Epub 2020 Sep 24.

2020
ASL Asti
AOU Città della Salute di Torino
ASL Vercelli
AO Cuneo
AOU Novara

Vignetti M; Foà R; Ghia P; Cimino G; Cavallari M; Cucci R; de la Serna J; Ferrarini I; Medina Perez A; Mauro FR; Coscia M; Di Raimondo F; Farina L; Molica S; Gaidano G; Doubek M; Ilariucci F; Tedeschi A; Marchetti M; Spacek M; Trentin L; Billio A; Ujjani CS; Roeker L; Orlandi EM; Schuster SJ; Shah NN; Sehgal AR; Pu JJ; et alii...

The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trial. in Cancer medicine / Cancer Med. 2020 Dec;9(23):8735-8746. doi: 10.1002/cam4.3396. Epub 2020 Nov 6.

2020
AOU San Luigi di Orbassano
AO Cuneo
AOU Città della Salute di Torino

Gallamini A; Rambaldi A; Massimo Gianni A; Chauvie S; Biggi A; Ferreri AJM; Viero P; Gini G; Zanotti R; Parvis G; Schiavotto C; Cimminiello M; Corradini P; Zoli V; Gavarotti P; Bolis S; Trentin L; La Nasa G; Cantonetti M; Picardi M; Rossi A; Patti C; Viviani S; Tarella C; Di Raimondo F; Pavoni C; Romano A;

Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial. in Haematologica / Haematologica. 2019 Nov;104(11):2241-2248. doi: 10.3324/haematol.2018.209932. Epub 2019 Apr 11.

2019
AOU San Luigi di Orbassano
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria

Tarella C; Ladetto M; Corradini P; Passera R; Gianni AM; Rambaldi A; Billio A; Gueli A; Mantoan B; Angrilli F; Perrone T; Semenzato G; Lanza F; Parvis G; Dondi A; Narni F; Zallio F; Zoli V; Devizzi L; Tucci A; Rota-Scalabrini D; Di Raimondo F; Stelitano C; Ciceri F; Rossini F; Castellino C; Gini G; Liberati AM; Musso M; et alii...

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. in Oncotarget / Oncotarget. 2017 Jun 27;8(45):79073-79086. doi: 10.18632/oncotarget.18674. eCollection 2017 Oct 3.

2017
AOU Città della Salute di Torino
AO Cuneo

Cuneo A; Cavo M; Vianelli N; Breccia M; Bacchi Reggiani ML; Merli F; Fanin R; Lemoli RM; Vitolo U; Di Raimondo F; Aversa F; Catani L; Sabattini E; Spinsanti M; De Matteis G; Anaclerico B; Cerqui E; de Marchi F; Scaffidi L; Di Veroli A; Latagliata R; Bosi C; Crugnola M; Ibatici A; Cavazzini F; Tieghi A; Bergamaschi M; Polverelli N; D'Adda M; et alii...

Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2016 Nov 20;34(33):4015-4022. doi: 10.1200/JCO.2016.67.2980. Epub 2016 Oct 31.

2016
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano

Rambaldi A; Boschini C; Delaini F; Masciulli A; Pileri S; Tabanelli V; Bruna R; Chilosi M; Falorio S; Flenghi L; Frezzato M; Trentin L; Gini G; La Nasa G; Benedetti F; Ferreri AJ; Di Raimondo F; Castellino C; Negri G; Piccin A; Billio A; Zoli V; Zanni M; Mulé A; Corradini P; Patti C; Di Nicola M; Gritti G; Rossi A; et alii...

The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma. in Journal of hematology & oncology / J Hematol Oncol. 2016 Mar 16;9:26. doi: 10.1186/s13045-016-0255-4.

2016
AO Cuneo

Gallamini A; Di Raimondo F; Romano A; Martino M; Porcella R; Lai S; Caria R; Celeghini I; Oppi S; Littera R; Greco M; La Nasa G; Carcassi C; Caocci G;

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21.

2014
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AO Cuneo
AOU Città della Salute di Torino

Montefusco V; Zambello R; Gottardi D; Franceschini L; Grasso M; Vincelli ID; Benevolo G; Levi A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Palumbo A; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; et alii...

Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. in British journal of haematology / Br J Haematol. 2011 Mar;152(5):551-60. doi: 10.1111/j.1365-2141.2010.08485.x. Epub 2010 Dec 20.

2011
AO Cuneo

Gianni AM; Chauvie S; Ficola U; Fallanca F; Barrington S; Biggi A; Rambaldi A; Leone M; Mulè A; Sorasio R; Gavarotti P; Feldman T; Stelitano C; Cantonetti M; Di Raimondo F; Fiore F; Rossi A; Viviani S; Gallamini A; Patti C;

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2007 Aug 20;25(24):3746-52. doi: 10.1200/JCO.2007.11.6525. Epub 2007 Jul 23.

2007
AO Cuneo

Biggi A; Vitolo U; Stelitano C; D'Amore F; Di Raimondo F; Loft A; Patti C; Hansen M; Merli F; Specht L; Rigacci L; Hutchings M; Gallamini A; Sancetta R; Trentin L; Luminari S; Iannitto E; Viviani S; Pierri I; Levis A;